UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 410

Sortiert nach

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

Haematologica (Roma), 2016-12, Vol.101 (12), p.1573

2016

Link zum Volltext

Verfügbarkeit prüfen

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

Haematologica (Roma), 2019-05, Vol.104 (5), p.e208

2019

Link zum Volltext

Verfügbarkeit prüfen

Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine

Journal of personalized medicine, 2024-06, Vol.14 (6), p.561

2024

Link zum Volltext

Verfügbarkeit prüfen

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

Haematologica (Roma), 2019-04, Vol.104 (4), p.797

2019

Link zum Volltext

Verfügbarkeit prüfen

P609: EFFECT OF LONG‐TERM ZANUBRUTINIB TREATMENT ON T‐CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB‐3111‐304 AND 305 TRIALS

HemaSphere, 2023-08, Vol.7 (S3), p.e18051e0-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

BLOOD, 2017, Vol.130, p.5353-5353

2017

Link zum Volltext

Verfügbarkeit prüfen

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

BLOOD, 2015-12, Vol.126 (23), p.1745-1745

2015

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region

Leukemia & lymphoma, 2014-08, Vol.55 (8), p.1774-1780

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia

British journal of haematology, 2009-01, Vol.144 (1), p.78-85

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression

British journal of haematology, 2012-12, Vol.159 (5), p.0-0

2012

Link zum Volltext

Verfügbarkeit prüfen

Strategies in the Management of Alemtuzumab-Related Side Effects

Seminars in oncology, 2006-04, Vol.33 (2 Suppl 5), p.29-35

2006

Link zum Volltext

Verfügbarkeit prüfen

Att skapa bilden av biblioteket: åtta bibliotekariers upplevelser av deltagandet i projektet futurum.kom

Karlsson, Claes

2011

Link zum Volltext

Verfügbarkeit prüfen

5.4 Phase-I-II Study of the Combination of Lenalidomide and Alemtuzumab in Patients with Advanced-Stage CLL

Clinical lymphoma, myeloma and leukemia, 2011-10, Vol.11, p.S244-S245

2011

Link zum Volltext

Verfügbarkeit prüfen

Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia

Current hematologic malignancy reports, 2009, Vol.4 (1), p.47-53

2009

Link zum Volltext

Verfügbarkeit prüfen

Targeted Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia

Karlsson, Claes

2010

Link zum Volltext
ProQuest

Strategies in the management of alemtuzumab-related side effects: The role of alemtuzumab (Campath) in the treatment of hematologic malignancies

Seminars in oncology, 2006, Vol.33 (2)

2006

Link zum Volltext

Verfügbarkeit prüfen

Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia

Medical oncology (Northwood, London, England), 2006-03, Vol.23 (1), p.137-139

2006

Link zum Volltext

Verfügbarkeit prüfen

Reconstitution of the T‐cell repertoire following treatment with alemtuzumab (anti‐CD52 monoclonal antibody) in patients with B‐cell chronic lymphocytic leukaemia

British journal of haematology, 2006-11, Vol.135 (4), p.475-485

2006

Link zum Volltext

Verfügbarkeit prüfen

research paper: Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia

British journal of haematology, 2006-11, Vol.135 (4), p.475-485

2006

Link zum Volltext

Verfügbarkeit prüfen

Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia

Medical oncology (Northwood, London, England), 2006, Vol.23 (1), p.137-140

2006

Link zum Volltext

Verfügbarkeit prüfen

Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Blood, 2005-11, Vol.106 (11), p.2986-2986

2005

Link zum Volltext

Verfügbarkeit prüfen

Stressor exposure and immunological response in man: Interferon-producing capacity and phagocytosis

Journal of psychosomatic research, 1976, Vol.20 (3), p.193-199

1976

Link zum Volltext

Verfügbarkeit prüfen

Analysis of urinary catecholamines: An improved auto-analyzer fluorescence method

Clinica chimica acta, 1974-02, Vol.51 (1), p.13-28

1974

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 410

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(389)
Mit Volltextzugriff
(374)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

P609: EFFECT OF LONG‐TERM ZANUBRUTINIB TREATMENT ON T‐CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB‐3111‐304 AND 305 TRIALS

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia

Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression

Strategies in the Management of Alemtuzumab-Related Side Effects

Att skapa bilden av biblioteket: åtta bibliotekariers upplevelser av deltagandet i projektet futurum.kom

5.4 Phase-I-II Study of the Combination of Lenalidomide and Alemtuzumab in Patients with Advanced-Stage CLL

Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia

Targeted Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia

Strategies in the management of alemtuzumab-related side effects: The role of alemtuzumab (Campath) in the treatment of hematologic malignancies

Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia

Reconstitution of the T‐cell repertoire following treatment with alemtuzumab (anti‐CD52 monoclonal antibody) in patients with B‐cell chronic lymphocytic leukaemia

research paper: Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia

Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia

Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Stressor exposure and immunological response in man: Interferon-producing capacity and phagocytosis

Analysis of urinary catecholamines: An improved auto-analyzer fluorescence method

Suchergebnisse filtern